Search results
Results from the WOW.Com Content Network
If you have a loved one with Alzheimer’s disease, you may have read about a newly approved drug. And you may have heard that the drug has caused some controversy. So, what’s really going on ...
The FDA’s approval of aducanumab last summer, though hailed by some Alzheimer’s advocacy groups, was met with intense criticism from some experts who raised questions about its effectiveness ...
The approval of aducanumab, despite the lack of evidence to support its therapeutic effects, led to controversy about the FDA’s approval process and a reluctance to prescribe the drug.
Aducanumab, sold under the brand name Aduhelm, is an anti-amyloid drug designed to treat Alzheimer's disease. [2] [3] It is a monoclonal antibody [3] [2] that targets aggregated forms (plaque) [4] [5] of amyloid beta (Aβ) found in the brains of people with Alzheimer's disease to reduce its buildup.
SEE MORE: What You Need To Know About The FDA-Approved Drug For Alzheimer's. The FDA has faced intense backlash since approving the drug, which costs $56,000 a year and requires monthly IVs. Three ...
This Dec. 21, 2022 image provided by Eisai in January 2023, shows vials and packaging for their medication Leqembi. On Friday, Jan. 6, 2023, U.S. health officials approved Leqembi, a new Alzheimer ...
The controversy stems from the questionable efficacy and potential side effects of the new drug but the debate it has sparked could reshape how we treat Alzheimer’s disease going forward.
The Food and Drug Administration has approved lecanemab, a drug developed by Eisai and Biogen with the goal of slowing the progression of Alzheimer’s disease. FDA grants full approval to new ...